Rapid Micro Biosystems
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 16.1m | 23.2m | 17.1m | 22.5m | 27.3m | 35.2m | 44.4m |
| % growth | (3 %) | 45 % | (26 %) | 31 % | 21 % | 29 % | 26 % |
| EBITDA | (29.0m) | (46.5m) | (63.2m) | (53.5m) | (46.4m) | (35.6m) | (25.4m) |
| % EBITDA margin | (180 %) | (200 %) | (369 %) | (237 %) | (170 %) | (101 %) | (57 %) |
| Profit | (37.1m) | (73.5m) | (60.8m) | (52.5m) | (46.4m) | (35.7m) | (26.7m) |
| % profit margin | (231 %) | (316 %) | (355 %) | (233 %) | (170 %) | (102 %) | (60 %) |
| EV / revenue | - | 10.6x | -3.6x | -2.7x | -0.6x | 0.0x | 0.4x |
| EV / EBITDA | - | -5.3x | 1.0x | 1.1x | 0.4x | -0.0x | -0.8x |
| R&D budget | 6.5m | 9.8m | 12.9m | 12.8m | - | - | - |
| R&D % of revenue | 41 % | 42 % | 75 % | 57 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$18.6m | Series A | ||
$6.7m | Early VC | ||
| N/A | $2.5m | Debt | |
$32.6m | Series B | ||
$6.0m | Early VC | ||
$25.0m | Series C | ||
$60.0m | Late VC | ||
* | N/A | Debt | |
$120m | Late VC | ||
$81.0m | Late VC | ||
| N/A | N/A | IPO | |
| Total Funding | €318m | ||
Related Content
Recent News about Rapid Micro Biosystems
EditRapid Micro Biosystems, Inc. is an innovative life sciences technology company specializing in automation solutions that streamline the manufacturing and expedite the release of healthcare products. The company serves large and complex pharmaceutical manufacturing operations, focusing on biologics, vaccines, cell and gene therapies, and sterile injectables. Rapid Micro Biosystems operates in the life sciences and healthcare market, providing mission-critical automation solutions that modernize microbial quality control (MQC) testing workflows. The company's flagship Growth platform automates these traditionally manual processes, enhancing efficiency and safety in product release. The business model revolves around selling and supporting its automation platforms, generating revenue through product sales, maintenance contracts, and service agreements.
Keywords: automation, life sciences, healthcare, microbial quality control, pharmaceutical, biologics, vaccines, cell therapy, gene therapy, sterile injectables.